Response to Interferon-α in Chronic Hepatitis B With and Without Precore Mutant Strain Detected by Mutation Site-specific Assay

Journal of Clinical Gastroenterology

Volumn 38, Issue 5, 2004, Pages 460-464

  Seo, Yasushi ^a   Yoon, Seitetsu ^a   Hamano, Kenichi ^a   Nakaji, Miyuki ^a   Yano, Yoshihiko ^a   Katayama, Megumi ^a   Ninomiya, Toshiaki ^a   Hayashi, Yoshitake ^a   Kasuga, Masato ^a  

^a KOBE UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

Chronic hepatitis B; Interferon ; Mutation site specific assay; Precore mutant

Indexed keywords

ALPHA INTERFERON; ANTIVIRUS AGENT;

ADULT; ARTICLE; COMPARATIVE STUDY; DRUG EFFECT; FEMALE; GENETICS; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; JAPAN; MALE; MUTATION; NUCLEOTIDE SEQUENCE; TREATMENT OUTCOME; VIROLOGY;

ADULT; ANTIVIRAL AGENTS; DNA MUTATIONAL ANALYSIS; FEMALE; HEPATITIS B VIRUS; HEPATITIS B, CHRONIC; HUMANS; INTERFERON-ALPHA; JAPAN; MALE; MUTATION; TREATMENT OUTCOME;

EID: 4344667937     PISSN: 01920790     EISSN: 15392031     Source Type: Journal    
DOI: 10.1097/00004836-200405000-00013     Document Type: Article

References (20)

1. Niederau C, Heintges T, Lange S, et al. Long-term follow-up of HBeAg-positive patients treated with interferon alfa for chronic hepatitis B. N Engl J Med. 1996;334:1422-1427.
2. Lok AS, Lai CL, Wu PC, et al. Treatment of chronic hepatitis B with interferon: experience in Asian patients. Semin Liver Dis. 1989;9:249-253.
3. Perrillo RP, Schiff ER, Davis GL, et al. A randomized, controlled trial of interferon alfa-2b alone and after prednisone withdrawal for the treatment of chronic hepatitis B. The Hepatitis Interventional Therapy Group. N Engl J Med. 1990;323:295-301.
4. Zhang X, Zoulim F, Habersetzer F, et al. Analysis of hepatitis B virus genotypes and pre-core region variability during interferon treatment of HBe antigen negative chronic hepatitis B. J Med Virol. 1996;48:8-16.
5. Brunetto MR, Giarin M, Saracco G, et al. Hepatitis B virus unable to secrete e antigen and response to interferon in chronic hepatitis B. Gastroenterology. 1993;105:845-850.
6. Naoumov NV, Thomas MG, Mason AL, et al. Genomic variations in the hepatitis B core gene: a possible factor influencing response to interferon alfa treatment. Gastroenterology. 1995;108:505-514.
7. Fattovich G, McIntyre G, Thursz M, et al. Hepatitis B virus precore/core variation and interferon therapy. Hepatology. 1995;22:1355-1362.
8. Lok AS, Akarca US, Greene S. Predictive value of precore hepatitis B virus mutations in spontaneous and interferon-induced hepatitis B e antigen clearance. Hepatology. 1995;21:19-24.
9. Aikawa T, Kanai K, Kako M, et al. Interferon-alpha 2a for chronic hepatitis B with e antigen or antibody:comparable antiviral effects on wild-type virus and precore mutant. J Viral Hepat. 1995;2:243-250.
10. Erhardt A, Reineke U, Blondin D, et al. Mutations of the core promoter and response to interferon treatment in chronic replicative hepatitis B. Hepatology. 2000;31:716-725.
11. Kinoshita M, Seno T, Fukui T, et al. A detection method for point mutation in the precore region of human hepatitis B virus (HBV)-DNA using mutation site-specific assay. Clin Chim Acta. 1994;228:83-90.
12. Tsubota A. Mutation site-specific assay (MSSA) for the detection of hepatitis B virus precore defective mutant in hepatitis B infection. Nippon Rinsho. 1995;53:321-324.
13. Oketani M, Oketani K, Xiaohong C, et al. Low level wild-type and pre-core mutant hepatitis B viruses and HBeAg negative reactivation of chronic hepatitis B. J Med Virol. 1999;58:332-337.
14. Shiraki K, Hamada M, Sugimoto K, et al. Detection of precore-mutant hepatitis B virus genome in patients with acute and fulminant hepatitis using mutation site-specific assay (MSSA). Hepatogastroenterology. 2002;49:1352-1356.
15. Hoofnagle JH, di Bisceglie AM. The treatment of chronic viral hepatitis. N Engl J Med. 1997;336:347-356.
16. Günther S, Meisel H, Reip A, et al. Frequent and rapid emergence of mutated pre-C sequences in HBV from e-antigen positive carriers who seroconvert to anti-HBe during interferon treatment. Virology. 1992;187:271-279.
17. Takeda K, Akahane Y, Suzuki H, et al. Defects in the precore region of the HBV genome in patients with chronic hepatitis B after sustained seroconversion from HBeAg to anti-HBe induced spontaneously or with interferon therapy. Hepatology. 1990;12:1284-1289.
18. Lampertico P, Manzin A, Rumi MG, et al. Hepatitis B virus precore mutants in HBeAg carriers with chronic hepatitis treated with interferon. J Viral Hepat. 1995;2:251-256.
19. Lok AS, Lai CL, Wu PC, et al. Long-term follow-up in a randomised controlled trial of recombinant alpha 2-interferon in Chinese patients with chronic hepatitis B infection. Lancet. 1988;2:298-302.
20. Bertoletti A, Sette A, Chisari FV, et al. Natural variants of cytotoxic epitopes are T-cell receptor antagonists for antiviral cytotoxic T cells. Nature. 1994;369:407-410.